(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), achieved significant sales in Europe, triggering a USD 25 million milestone payment from partner Pfizer. This achievement highlights Cresemba’s strong performance in treating severe fungal infections. The milestone … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Basilea Pharmaceutica, Cresemba®, David Veitch, Financial, fungal infections, investment
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) announced a significant milestone with a USD 1.25 million payment triggered by the robust sales performance of its antifungal medication, Cresemba® (isavuconazole), in the Asia Pacific region and China by its license partner … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Security & Safety, Switzerland, Technology
Tagged Asia Pacific, Basilea Pharmaceutica, CHINA, Cresemba®, David Veitch, Financial, investment
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN), a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced an asset purchase agreement with Spexis AG (SIX: SPEX) for a preclinical antibiotics program aimed at combating Gram-negative bacteria, including … Read the full press release
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced robust financial results for the first half-year ending June 30, 2023. Their CEO, David Veitch, highlighted the company’s progress in executing their … Read the full press release
Posted in Business, Financial, Healthcare, Management, Marketing, News, Pharma & Biotech, Science, Switzerland
Tagged Adesh Kaul, Basilea Pharmaceutica, Cresemba®, David Veitch, financial results, Zevtera®
Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX: BSLN), a commercial stage biopharmaceutical company, has announced the company has secured non-dilutive refinancing in the amount of CHF 75 … Read the full press release
Annonce ad hoc conformément à l’art. 53LR (COMMUNIQUÉ DE PRESSE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX : BSLN), une société biopharmaceutique au stade commercial, a annoncé la La société a obtenu un refinancement non dilutif d’un montant … Read the full press release
BASEL, 05-Mar-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea’s Management Committee as Chief Corporate Development Officer effective March 01, 2018. He will continue to be responsible for strategic planning, business development & … Read the full press release
Posted in Pharma & Biotech, Switzerland
Tagged Adesh Kaul, Basilea Pharmaceutica, leadership, Management, pharma, Ronald Scott
BASEL, 09-Jun-2017 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase 1/2a program with its anticancer drug candidate BAL101553, a novel tumor checkpoint controller, at the American Society of Clinical Oncology … Read the full press release
Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. QIDP status provides priority review and … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Switzerland
Tagged Barbara Zink, Basilea Pharmaceutica, fungal infections, invasive aspergillosis, Isavuconazole, isavuconazonium sulfate, Peer Nils Schröder, QIDP, Qualified Infectious Disease Product, Ronald Scott, treatment, U.S. FDA, zygomycosis
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
